Developing cancer cures is top priority for Americans, survey shows

5 August 2013

A new survey commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA) shows 86% of Americans believe developing cures for more forms of cancer should be one of the top national health priorities, followed by developing effective treatments for heart disease (78%) and more intensive medical care for seniors (76%).

These findings are the result of a new annual “From Hope to Cures” survey, which explores Americans’ attitudes on personal health and medical concerns.

“A patient-centric dialogue is crucial to improving health outcomes,” said John Castellani, president and chief executive of PhRMA, adding: “The Health Survey findings will help also inform efforts to address major health challenges such as chronic disease, improved prevention and wellness activities and enhanced patient adherence to prescribed therapies.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical